Allianz Asset Management
TVRD

Allianz Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Allianz Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-414
Closed -$323K – 2495
2021
Q1 		$323K Buy
+414
New +$283K ﹤0.01% 2033
2020
Q2 		– Sell
-1,163
Closed -$553K – 2574
2020
Q1 		$553K Sell
1,163
-278
-19% -$151K ﹤0.01% 2019
2019
Q4 		$836K Buy
1,441
+291
+25% +$204K ﹤0.01% 2261
2019
Q3 		$757K Sell
1,150
-1,665
-59% -$1.38M ﹤0.01% 2229
2019
Q2 		$2.18M Sell
2,815
-636
-18% -$447K ﹤0.01% 1851
2019
Q1 		$2.44M Buy
3,451
+12
+0.3% +$7.18K ﹤0.01% 1775
2018
Q4 		$1.61M Buy
3,439
+462
+16% +$298K ﹤0.01% 1837
2018
Q3 		$2.57M Buy
2,977
+256
+9% +$185K ﹤0.01% 1847
2018
Q2 		$1.88M Sell
2,721
-15
-0.5% -$7.63K ﹤0.01% 1972
2018
Q1 		$1.22M Sell
2,736
-55
-2% -$26.7K ﹤0.01% 2126
2017
Q4 		$1.23M Sell
2,791
-37
-1% -$16.9K ﹤0.01% 2173
2017
Q3 		$1.39M Sell
2,828
-6
-0.2% -$3K ﹤0.01% 2135
2017
Q2 		$1.57M Sell
2,834
-517
-15% -$328K ﹤0.01% 2069
2017
Q1 		$2.22M Sell
3,351
-3,884
-54% -$2.07M ﹤0.01% 1958
2016
Q4 		$2.42M Sell
7,235
-3,258
-31% -$1.05M ﹤0.01% 1897
2016
Q3 		$3.15M Buy
10,493
+486
+5% +$105K ﹤0.01% 1803
2016
Q2 		$1.73M Sell
10,007
-2,260
-18% -$492K ﹤0.01% 1988
2016
Q1 		$2.75M Sell
12,267
-56
-0.5% -$16.7K ﹤0.01% 1665
2015
Q4 		$7.48M Buy
12,323
+7,021
+132% +$3.85M 0.01% 1182
2015
Q3 		$2.73M Buy
+5,302
New +$3.55M ﹤0.01% 1499

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Allianz Asset Management's TVRD Position: Q2 2021 in Review

Allianz Asset Management sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 414 shares — an estimated $323K sold.

Allianz Asset Management first reported a position in TVRD in Q3 2015 and held it in 20 quarters. The position peaked at $7.48M in Q4 2015. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Allianz Asset Management reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Allianz Asset Management sold 414 Tvardi Therapeutics shares in Q2 2021, an estimated $323K.
  • Allianz Asset Management first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 20 quarters.
  • Allianz Asset Management's Tvardi Therapeutics position peaked at $7.48M in Q4 2015.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Allianz Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.